Scrip Intelligence, which programs the yearly Scrip Awards, has named Regeneron Pharmaceuticals (NASDAQ: REGN) as “Biotechnology Company of the Year” at the 8th iteration of the awards this year.
From the Sacramento Bee:
Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron, said, “We are honored to be recognized by Scrip, a leading industry publication. This has indeed been a transforming time for Regeneron, as we went from having one approved drug to three, advanced investigational drugs into Phase 3 trials, and created shareholder value that moved Regeneron into the top ranks of the biotechnology industry.”
The award recognizes high achievements in the biotech sector within the year for which it is given. The winners are selected by a panel of 16 members representing leaders in the pharmaceutical industry and related research.
Scrip’s award citation ran:
“Regeneron has been transformed over the past year by the U.S. approval of its first major product. On the back of its highly successful launch, the company expects to become profitable for the first time in 2012.”
Regeneron markets three main products in the U.S.: the EYELEA® (aflibercept) Injection, ZALTRAP® (ziv-zflibercept) Injection meant for IV application, and ARCALYST® (rilonacept) Injection, meant for subcutaneous use.
Regeneron’s focus includes ophthalmology, inflammation, cancer research, and hypercholesterolemia.
